Vertex Pharmaceuticals Incorporated
NASDAQ Global SelectRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- Vertex Pharmaceuticals Incorporated (VRTX), headquartered in Boston, Massachusetts and founded in 1989, develops, manufactures and commercializes transformative medicines for serious diseases, with a primary focus on cystic fibrosis, sickle cell disease, beta thalassemia and emerging areas including pain, kidney disease and type 1 diabetes; its portfolio features the CFTR modulators TRIKAFTA/KAFTRIO, ALYFTREK, SYMDEKO/SYMKEVI, ORKAMBI and KALYDECO, the CRISPR/Cas9 gene-edited therapy CASGEVY (co-developed with CRISPR Therapeutics), the non-opioid NaV1.7 pain treatment JOURNAVX/suzetrigine, and investigational assets such as povetacicept (for IgA nephropathy and other autoimmune kidney diseases), inaxaplin (for APOL1-mediated kidney disease), VX-407 (for autosomal dominant polycystic kidney disease), VX-522 (CFTR mRNA therapy with Moderna), VX-880/VX-264 (stem cell therapies for type 1 diabetes) and VX-993 (next-generation pain candidate); the company operates research facilities in San Diego, California and Milton Park, Oxfordshire, UK, with commercial presence across North America, Europe, Australia, Asia and the Middle East. In recent developments, Vertex completed its $4.9 billion acquisition of Alpine Immune Sciences in 2024 to secure povetacicept, entered an exclusive collaboration with Ono Pharmaceutical in June 2025 for povetacicept commercialization in Japan and South Korea (building on a prior deal with Zai Lab), launched ALYFTREK in the US and began European reimbursement efforts in England, Germany and Denmark, advanced CASGEVY and JOURNAVX launches with expanding US coverage including major PBMs and hospital networks, completed Phase 3 enrollment for povetacicept in IgA nephropathy (targeting accelerated US approval in H1 2026), initiated VX-407 Phase 2 proof-of-concept for ADPKD, progressed VX-522 Phase 1/2 data readout in H1 2025 and discontinued standalone development of an experimental pain drug following mid-stage failure while prioritizing suzertrigine/JOURNAVX expansion. Vertex reported Q3 2025 total revenues of $3.08 billion (up 11% year-over-year), driven by CF franchise growth, early new product contributions and favorable US pricing, with full-year 2025 guidance refined to $11.9-12.0 billion.
Company News
3 Stocks Whose Competitive Walls Tower Over Nvidia's
Why Is Vertex (VRTX) Up 14.4% Since Last Earnings Report?
Vertex Completes Acquisition of Crinetics Pharmaceuticals and Announces Expansion of Executive Leadership Team
Ancora Advisors LLC Acquires Shares of 1,127 Vertex Pharmaceuticals Incorporated $VRTX
17,047 Shares in Vertex Pharmaceuticals Incorporated $VRTX Acquired by Beacon Pointe Advisors LLC
Breakfast News: Nvidia Crushed It. Who Cares?
Vertex to Participate in Upcoming September Investor Conferences
EP Wealth Advisors LLC Acquires New Position in Vertex Pharmaceuticals Incorporated $VRTX
Advisors Capital Management LLC Buys Shares of 1,258 Vertex Pharmaceuticals Incorporated $VRTX
Allworth Financial LP Invests $2.23 Million in Vertex Pharmaceuticals Incorporated $VRTX
Uber, ServiceNow And A Health Care Stock On CNBC's ‘Final Trades'
In Healthcare ETFs, Is iShares Pharma a Better Buy Than VanEck Biotech?
Vertex Pharmaceuticals' Rally Has a New Engine -- and Wall Street Thinks the Best Is Still Ahead
AssuredPartners Investment Advisors LLC Invests $2.06 Million in Vertex Pharmaceuticals Incorporated $VRTX
Crinetics Pharmaceuticals Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Crinetics Pharmaceuticals, Inc. - CRNX
Crinetics Pharmaceuticals Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Crinetics Pharmaceuticals, Inc. - CRNX
Vertex Pharmaceuticals Just Hit an All-Time High. Here's Why the Biotech Stock Could Soar Even More
Vertex Pharmaceuticals: I Was Wrong About Its Near-Term Prospects (Rating Upgrade)
Why Vertex Pharmaceuticals Stock Ticked Higher on Tuesday
VRTX's Q2 Earnings Lag Estimates, Revenues Top, 2026 Sales View Raised